(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of -0.02% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Viatris's revenue in 2024 is $15,361,200,000.On average, 1 Wall Street analysts forecast VTRS's revenue for 2024 to be $18,030,082,444,646, with the lowest VTRS revenue forecast at $18,030,082,444,646, and the highest VTRS revenue forecast at $18,030,082,444,646. On average, 2 Wall Street analysts forecast VTRS's revenue for 2025 to be $18,243,582,525,751, with the lowest VTRS revenue forecast at $18,047,287,710,230, and the highest VTRS revenue forecast at $18,439,877,341,271.
In 2026, VTRS is forecast to generate $18,277,106,003,435 in revenue, with the lowest revenue forecast at $18,151,364,683,569 and the highest revenue forecast at $18,402,847,323,300.